Print  |  Close

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma


Active: No
Cancer Type: Multiple Myeloma NCT ID: NCT04045028
Trial Phases: Phase I Protocol IDs: GO41036 (primary)
NCI-2019-06145
Eligibility: 18 Years and older, Male and Female Study Type: Treatment
Study Sponsor: Genentech Inc.
NCI Full Details: http://clinicaltrials.gov/show/NCT04045028

Summary

This is a Phase I open-label, multicenter study designed to evaluate the safety,
tolerability, pharmacokinetics, pharmacodynamics, and preliminary activity of tiragolumab
administered as a single agent or in combination with atezolizumab and/or daratumumab or
rituximab in participants with relapsed or refractory (R/R) multiple myeloma (MM) or R/R
non-Hodgkin lymphoma (NHL).

Objectives

In the Phase Ia part of the study, tiragolumab is administered as a single agent in
participants with R/R MM or R/R NHL.

In the Phase Ib part of the study, tiragolumab is administered in combination with
atezolizumab and/or daratumumab in participants with R/R MM or with rituximab in participants
with R/R NHL.

Treatment Sites in Georgia

Emory Clinic
1365 Clifton Road NE
Atlanta, GA 30322
www.emoryhealthcare.org

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.